HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Mucoactive agents for chronic, non-cystic fibrosis lung disease: A systematic review and meta-analysis.

Abstract
Inhaled mucoactive agents are used in respiratory disease to improve mucus properties and enhance secretion clearance. The effect of mannitol, recombinant human deoxyribonuclease/dornase alfa (rhDNase) and hypertonic saline (HS) or normal saline (NS) are not well described in chronic lung conditions other than cystic fibrosis (CF). The aim of this review was to determine the benefit and safety of inhaled mucoactive agents outside of CF. We searched Medline, Embase, CINAHL and CENTRAL for randomized controlled trials investigating the effects of mucoactive agents on lung function, adverse events (AEs), health-related quality of life (HRQOL), hospitalization, length of stay, exacerbations, sputum clearance and inflammation. There were detrimental effects of rhDNase in bronchiectasis, with average declines of 1.9-4.3% in forced expiratory volume in 1 s (FEV1 ) and 3.7-5.4% in forced vital capacity (FVC) (n = 410, two studies), and increased exacerbation risk (relative risk = 1.35, 95% CI = 1.01-1.79 n = 349, one study). Some participants exhibited a reduction in FEV1 (≥10-15%) with mucoactive agents on screening (mannitol = 158 of 1051 participants, rhDNase = 2 of 30, HS = 3 of 80). Most AEs were mild and transient, including bronchospasm, cough and breathlessness. NS eased symptomatic burden in COPD, while NS and HS improved spirometry, HRQOL and sputum burden in non-CF bronchiectasis. Mannitol improved mucociliary clearance in asthma and bronchiectasis, while the effects of N-acetylcysteine were unclear. In chronic lung diseases outside CF, there are small benefits of mannitol, NS and HS. Adverse effects of rhDNase suggest this should not be administered in non-CF bronchiectasis.
AuthorsBenjamin J Tarrant, Caitlin Le Maitre, Lorena Romero, Ranjana Steward, Brenda M Button, Bruce R Thompson, Anne E Holland
JournalRespirology (Carlton, Vic.) (Respirology) Vol. 22 Issue 6 Pg. 1084-1092 (08 2017) ISSN: 1440-1843 [Electronic] Australia
PMID28397992 (Publication Type: Journal Article, Meta-Analysis, Review, Systematic Review)
Copyright© 2017 Asian Pacific Society of Respirology.
Chemical References
  • Expectorants
  • Recombinant Proteins
  • Saline Solution, Hypertonic
  • Mannitol
  • Deoxyribonuclease I
  • dornase alfa
  • Mesna
  • Acetylcysteine
Topics
  • Acetylcysteine (pharmacology, therapeutic use)
  • Administration, Inhalation
  • Bronchiectasis (drug therapy, physiopathology)
  • Chronic Disease
  • Deoxyribonuclease I (pharmacology, therapeutic use)
  • Expectorants (pharmacology, therapeutic use)
  • Forced Expiratory Volume
  • Humans
  • Lung Diseases (drug therapy, physiopathology)
  • Mannitol (pharmacology, therapeutic use)
  • Mesna (therapeutic use)
  • Mucociliary Clearance (drug effects)
  • Quality of Life
  • Recombinant Proteins (pharmacology, therapeutic use)
  • Saline Solution, Hypertonic (pharmacology, therapeutic use)
  • Symptom Flare Up
  • Vital Capacity

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: